Trial
NCT00199342
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Kyowa Kirin, Inc.
Collaborators
—
Condition
Stage IV Melanoma
Intervention
KW-2871
Why stopped
Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-03